179 related articles for article (PubMed ID: 31173259)
1. miR‑29 promoter and enhancer methylation identified by pyrosequencing in Burkitt lymhoma cells: Interplay between MYC and miR‑29 regulation.
Mazzoccoli L; Robaina MC; Bacchi CE; Soares Lima SC; Klumb CE
Oncol Rep; 2019 Aug; 42(2):775-784. PubMed ID: 31173259
[TBL] [Abstract][Full Text] [Related]
2. MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.
Mazzoccoli L; Robaina MC; Apa AG; Bonamino M; Pinto LW; Queiroga E; Bacchi CE; Klumb CE
J Cancer Res Clin Oncol; 2018 Mar; 144(3):483-497. PubMed ID: 29318382
[TBL] [Abstract][Full Text] [Related]
3. Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis.
Robaina MC; Mazzoccoli L; Arruda VO; Reis FR; Apa AG; de Rezende LM; Klumb CE
Exp Mol Pathol; 2015 Apr; 98(2):200-7. PubMed ID: 25746661
[TBL] [Abstract][Full Text] [Related]
4. The 5' regulatory sequences of active miR-146a promoters are hypomethylated and associated with euchromatic histone modification marks in B lymphoid cells.
Szenthe K; Koroknai A; Banati F; Bathori Z; Lozsa R; Burgyan J; Wolf H; Salamon D; Nagy K; Niller HH; Minarovits J
Biochem Biophys Res Commun; 2013 Apr; 433(4):489-95. PubMed ID: 23528241
[TBL] [Abstract][Full Text] [Related]
5. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.
Onnis A; De Falco G; Antonicelli G; Onorati M; Bellan C; Sherman O; Sayed S; Leoncini L
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20930934
[TBL] [Abstract][Full Text] [Related]
6. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma.
Seitz V; Butzhammer P; Hirsch B; Hecht J; Gütgemann I; Ehlers A; Lenze D; Oker E; Sommerfeld A; von der Wall E; König C; Zinser C; Spang R; Hummel M
PLoS One; 2011; 6(11):e26837. PubMed ID: 22102868
[TBL] [Abstract][Full Text] [Related]
7. Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim.
Paschos K; Smith P; Anderton E; Middeldorp JM; White RE; Allday MJ
PLoS Pathog; 2009 Jun; 5(6):e1000492. PubMed ID: 19557159
[TBL] [Abstract][Full Text] [Related]
8. Viral driven epigenetic events alter the expression of cancer-related genes in Epstein-Barr-virus naturally infected Burkitt lymphoma cell lines.
Hernandez-Vargas H; Gruffat H; Cros MP; Diederichs A; Sirand C; Vargas-Ayala RC; Jay A; Durand G; Le Calvez-Kelm F; Herceg Z; Manet E; Wild CP; Tommasino M; Accardi R
Sci Rep; 2017 Jul; 7(1):5852. PubMed ID: 28724958
[TBL] [Abstract][Full Text] [Related]
9. Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines.
Jansson A; Masucci M; Rymo L
J Virol; 1992 Jan; 66(1):62-9. PubMed ID: 1370095
[TBL] [Abstract][Full Text] [Related]
10. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
11. Sequence-specific methylation inhibits the activity of the Epstein-Barr virus LMP 1 and BCR2 enhancer-promoter regions.
Minarovits J; Hu LF; Minarovits-Kormuta S; Klein G; Ernberg I
Virology; 1994 May; 200(2):661-7. PubMed ID: 8178450
[TBL] [Abstract][Full Text] [Related]
12. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
13. Decitabine represses translocated MYC oncogene in Burkitt lymphoma.
Guan H; Xie L; Klapproth K; Weitzer CD; Wirth T; Ushmorov A
J Pathol; 2013 Apr; 229(5):775-83. PubMed ID: 23341364
[TBL] [Abstract][Full Text] [Related]
14. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
15. Integrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma.
Oduor CI; Kaymaz Y; Chelimo K; Otieno JA; Ong'echa JM; Moormann AM; Bailey JA
BMC Cancer; 2017 Nov; 17(1):761. PubMed ID: 29132323
[TBL] [Abstract][Full Text] [Related]
16. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression.
Leucci E; Onnis A; Cocco M; De Falco G; Imperatore F; Giuseppina A; Costanzo V; Cerino G; Mannucci S; Cantisani R; Nyagol J; Mwanda W; Iriso R; Owang M; Schurfeld K; Bellan C; Lazzi S; Leoncini L
Int J Cancer; 2010 Mar; 126(6):1316-26. PubMed ID: 19530237
[TBL] [Abstract][Full Text] [Related]
17. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation.
Leucci E; Cocco M; Onnis A; De Falco G; van Cleef P; Bellan C; van Rijk A; Nyagol J; Byakika B; Lazzi S; Tosi P; van Krieken H; Leoncini L
J Pathol; 2008 Dec; 216(4):440-50. PubMed ID: 18802929
[TBL] [Abstract][Full Text] [Related]
18. Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas.
Piccaluga PP; Navari M; De Falco G; Ambrosio MR; Lazzi S; Fuligni F; Bellan C; Rossi M; Sapienza MR; Laginestra MA; Etebari M; Rogena EA; Tumwine L; Tripodo C; Gibellini D; Consiglio J; Croce CM; Pileri SA; Leoncini L
Oncotarget; 2016 Jan; 7(1):224-40. PubMed ID: 26325594
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
[TBL] [Abstract][Full Text] [Related]
20. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
